In conclusion, our in vitro18 and present in vivo data shows a novel mechanism of action of the FDA approved anthelmintic drug niclosamide, which could provide a new and practical approach for treating T2D in people with obesity and defects in glucagon signalling. This evidence concerns the gene GCG and obesity disorder.